Skip to main content

Table 2 Relative changes in DCE-MRI parameters compared with baseline values at 1 h, 24 h, and 21 days after the first dose of bevacizumab in eight patients with breast cancer with brain metastases

From: A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer

Parameters Baseline Δ1 h(%) Δ24 h(%) Δ21 Days(%)
Peak 223.3 ± 47.2 −12.8 ± 4.6 −24.7 ± 7.9 −27 ± 8.6
Slope 1.5 ± 1.1 −46.6 ± 26.5 −65.8 ± 20.6 −52.8 ± 27.7
iAUC 60 49820 ± 31258 −27.9 ± 15 −55.5 ± 11.1 −58.1 ± 15
Ktrans (min -1  x 1000) 858.1 ± 1194.7 −46.6 ± 27.6 −63.9 ± 31.2 −78.2 ± 23.9
  1. Data are presented as the mean ± standard deviations (SD). The Wilcoxon signed-rank test had P < .01 compared with the baseline DCE-MRI data